Hagen Brett R
Chief Accounting Officer
Hagen Brett R has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Mar 23, 2026.
On the most recent filing, Hagen Brett R is listed as Chief Accounting Officer at Kalaris Therapeutics, Inc. Inside the rolling window, Hagen Brett R reported no open-market purchases and 1 open-market sale totaling $13K in KLRS.
Companies traded
Other insiders at KLRS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hagen Brett R made?
Hagen Brett R has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Hagen Brett R trade?
Hagen Brett R has filed SEC Form 4 disclosures for 1 company, including KLRS.
When was Hagen Brett R's most recent SEC Form 4 filing?
Hagen Brett R's most recent SEC Form 4 filing on Tracefour is dated Mar 23, 2026.
What is Hagen Brett R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hagen Brett R is listed as Chief Accounting Officer.
What is Hagen Brett R's total buy and sell value in the current window?
Inside the rolling retention window, Hagen Brett R bought $0 and sold $13K based on SEC Form 4 filings.
What was Hagen Brett R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,915 KLRS shares on 2026-03-20, worth $13K, per SEC Form 4 filings.